MorphoSys has dosed the first patient dosing in a multicentre, open-label, dose- escalation Phase I/IIa trial evaluating cancer antibody MOR202.
MOR202 is a fully human HuCAL antibody that is directed against CD38, a therapeutic target highly expressed in multiple myeloma tumour cells and certain leukaemias.
A maximum of 82 patients will be enrolled in the trial, which will investigate the safety, tolerability, pharmacokinetics and preliminary efficacy of MOR202 in people with relapsed or refractory multiple myeloma.
In the trial, the patients are expected to be treated with different doses of the HuCAL-derived antibody MOR202.
MorphoSys chief development officer Arndt Schottelius said they will evaluate MOR202 both as a monotherapy and in combination with standard therapy.
